Welcome to our dedicated page for Palisade Bio SEC filings (Ticker: PALI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Palisade Bio, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical issuer developing oral PDE4 inhibitor prodrugs. Disclosures include proxy materials for annual and special stockholder meetings, director elections, auditor ratification, charter-amendment voting matters and compensation-plan governance.
Material-event reports and registration statements cover clinical-development service arrangements, common-stock sales, securities registration, capital-structure updates, Nasdaq listing compliance and meeting adjournment or withdrawal actions. The filings also provide formal context for PALI-2108 development activities, equity financing mechanics, corporate governance and public-company reporting obligations.
Palisade Bio, Inc. Schedule 13G: Soleus Capital Master Fund, L.P. and related Soleus entities report shared beneficial ownership of 9,353,687 shares of Palisade Bio common stock. The filing states this represents 5.4% of the class based on 173,579,670 shares outstanding as of May 7, 2026.
The report attributes the shares to the Master Fund and discloses the management and ownership chain (Soleus Capital, LLC; Soleus Capital Group, LLC; Soleus Capital Management, L.P.; Soleus GP, LLC) and Guy Levy as managing member. The filing includes customary disclaimers that the other entities and Mr. Levy disclaim beneficial ownership except for Section 13(d) obligations.
Palisade Bio reports aggregated beneficial ownership disclosures by RA Capital and related reporting persons as of 03/31/2026. The report shows each Reporting Person beneficially owns 17,620,479 shares, representing 9.99% of the common stock on a controlled‑ownership basis due to a pre‑funded warrant blocker.
The Fund directly holds 7,124,116 shares and holds pre‑funded warrants exercisable for up to 16,614,285 shares, but exercise is limited so beneficial ownership does not exceed 9.99%. The filing cites 165,884,817 shares outstanding as of 03/18/2026 and 10,494,363 shares issuable upon exercise of the Pre‑Funded Warrants for percentage calculation purposes.
Palisade Bio, Inc. reports a Schedule 13G/A showing Point72-affiliated parties beneficially own 411,772 shares of common stock, representing 0.2% of the class as of March 31, 2026.
The filing states Point72 Asset Management and Point72 Capital Advisors, Inc. hold these shares through investment management arrangements and that Steven A. Cohen controls those entities. The report lists shared voting and dispositive power of 411,772 shares for each reporting person; all figures are reported as of the close of business on March 31, 2026.
Palisade Bio, Inc. beneficial ownership update: Commodore Capital reports beneficially owning 12,366,776 shares of Common Stock as of March 31, 2026, equal to 7.2% based on 167,421,702 shares reported outstanding. The total includes 5,185,714 shares issuable upon exercise of a Pre-Funded Warrant, which is subject to a 9.99% Beneficial Ownership Limitation.
Palisade Bio, Inc. receives a Schedule 13G/A reporting a 7.9% beneficial ownership stake held collectively by Perceptive Advisors, Joseph Edelman and Perceptive Life Sciences Master Fund.
The filing states the Reporting Persons share voting and dispositive power over 14,113,863 shares of Common Stock. The ownership percentages are calculated using 173,579,670 shares outstanding as of May 7, 2026 and assume exercise of 5,185,714 Pre-Funded Warrants subject to a 9.99% Beneficial Ownership Limitation.
Palisade Bio, Inc. reported institutional holdings disclosed on a Schedule 13G. Ameriprise Financial, Inc. and its affiliate Columbia Management Investment Advisers, LLC report shared voting and dispositive power over 8,711,385 shares, representing 5.3% of the class as shown on the cover page.
The filing states AFI is the parent of CMIA and includes CMIA's reported holdings; both entities disclaim beneficial ownership. Signature and exhibit references identify a subsidiary and a joint filing agreement.
Palisade Bio, Inc. filed a shelf registration on to offer up to $300,000,000 of common stock, preferred stock, debt securities, warrants and units from time to time. The prospectus describes general terms; specific amounts, prices and offering methods will be provided in future prospectus supplements. The filing notes completed Phase 1/1b clinical programs for lead candidate PALI-2108, reporting dosing of 89 subjects across healthy volunteer and UC cohorts and five FSCD patients in an exploratory cohort, with company statements of favorable safety, tolerability, pharmacokinetics and pharmacodynamic target engagement. The company states plans for IND submissions and to initiate a Phase 2 UC trial in Q3 2026. The prospectus discloses governance, capitalization, outstanding derivative instruments, and routine risk factors related to development, regulatory approval and financing.
Palisade Bio reported first quarter 2026 results and highlighted progress of its lead IBD candidate, PALI-2108. The company completed Phase 1a/1b studies with favorable safety, target engagement in ileum and colon tissue, and early clinical activity, and is preparing Phase 2 trials in ulcerative colitis and Crohn’s disease starting in 3Q 2026 and 1Q 2027, respectively.
Research and development expenses rose to $6.4 million and general and administrative expenses to $4.4 million, driving a net loss of $9.6 million for the quarter. Palisade ended March 31, 2026 with $132.6 million in cash and cash equivalents and expects this to fund operations through Phase 2 efficacy readouts for PALI-2108 in 2027 and early 2028.
Palisade Bio, Inc. reported a larger quarterly loss as it ramps development of its lead IBD drug candidate, but ended the period with substantial cash. For the three months ended March 31, 2026, net loss widened to $9.6 million from $2.2 million a year earlier, driven by higher research and development and general and administrative spending. Research and development expenses rose to $6.4 million, reflecting increased clinical trial and manufacturing activity for PALI-2108 and higher stock-based compensation. General and administrative costs increased to $4.4 million, also largely from stock-based compensation and higher legal fees. The company generated $1.1 million of other income from money market investments following a large equity raise in 2025. Palisade ended the quarter with $132.6 million in cash, cash equivalents and restricted cash and believes this will fund key Phase 2 trials through efficacy readouts in ulcerative colitis and Crohn’s disease. Management still reports a material weakness in internal control over financial reporting and is pursuing remediation.